House Committee on Oversight and Government Reform Chairman James Comer has raised significant concerns over the potential risks to national security and data privacy following 23andMe’s bankruptcy filing. The direct-to-consumer genetic testing company, which holds DNA data of millions of Americans, filed for Chapter 11 bankruptcy on March 23, 2025.
Comer emphasized the importance of protecting Americans’ genetic information from misuse by foreign and domestic entities. He highlighted potential threats from foreign nations like the Chinese Communist Party (CCP) and other dangers such as discriminatory practices in insurance, credit, and advertising. “It is imperative that 23andMe—and all companies handling genetic data—ensure there is no legal or illegal pathway for foreign adversaries or hostile private entities to access, manipulate, or exploit Americans’ DNA,” Comer stated.
The hearing also addressed the ongoing sale process of 23andMe’s assets. Regeneron Pharmaceuticals announced an agreement to acquire the company on May 19, 2025. However, a court decision on June 4 reopened the auction for final bids from Regeneron and TTAM Research Institute, founded by Anne Wojcicki, co-founder and former CEO of 23andMe.
Concerns were further amplified by past incidents involving foreign investments in 23andMe. In 2015, WuXi Healthcare Ventures invested $115 million in the company. Although this partnership was reportedly terminated, questions remain about future ownership potentially engaging with “bad foreign actors.”
In addition to national security concerns tied to possible partnerships with entities like Zai Lab Limited during COVID-19 drug trials with Regeneron, previous hacking incidents have exposed personal information from nearly seven million profiles.
The Department of Defense had previously advised military personnel against using consumer DNA kits due to security risks associated with genetic data collection by private companies.
Comer concluded that Congress might need to take legislative action to protect Americans’ personal genetic data better. The hearing included testimonies from Anne Wojcicki and interim CEO Joseph Selsavage regarding these pressing issues while adhering to court-mandated restrictions on disclosing certain aspects of the bankruptcy proceedings.
